At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 35 enrolled
Drug / intervention
LEO 90100 Aerosol foam +1 moredrug
Likely dose
Betesil® 2.25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a Trial Evaluating the Anti-psoriatic Effect of LEO 90100 Aerosol Foam Compared to Betesil® Medicated Plaster in the Treatment of Psoriasis Vulgaris
In Brief
A Phase 2 clinical trial evaluating LEO 90100 Aerosol foam and Betesil® 2.25 mg for Skin and Connective Tissue Diseases. Completed, enrolled 35 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the anti-psoriatic effect of LEO 90100 aerosol foam compared with Betesil® medicated plaster
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSkin and Connective Tissue Diseases
CountriesFrance
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartAug 2015
First PostedAug 2015
Primary CompletionJan 2016
TodayJul 2026
First PostedAug 7, 2015
Enrollment StartAug 1, 2015
Primary CompletionJan 1, 2016
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 10.9 years ago
Interventions
LEO 90100 Aerosol foamdrug
Betesil® 2.25 mgdrug